Izuralimab(TD-HV702046) is a research-grade recombinant antibody targetingCD278. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.
Species reactivity
Human
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species
Humanized
Isotype
half-IGG1-kappa/(scFv-kappa-heavy)-h-CH2-CH3
Clonality
Monoclonal
Target
CD278, ICOS, Inducible T-cell costimulator, Activation-inducible lymphocyte immunomediatory molecule, AILIM, Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279
Endotoxin level
Please contact the lab for this information.
Purity
>95% purity as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9Y6W8 & Q15116
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names
Bispecific, XmAb-23104, 2329669-80-7
Background
Izuralimab is a bispecific IgG1 antibody targeting inducible T-cell costimulator (ICOS/CD278) and PD-1.
Caption
SDS-PAGE for Research Grade Izuralimab
Note
For research use only. Not suitable for clinical or therapeutic use.
抗体
试剂盒
多肽
蛋白
组织芯片
定制服务咨询